Navigation Links
Data Presented on Cempra Pharmaceutical's CEM-101 at the Infectious Diseases Society of America Annual Meeting Reinforces Potency and Coverage Against Multidrug-Resistant S. Pneumoniae Isolates
Date:10/28/2009

CHAPEL HILL, N.C., Oct. 29 /PRNewswire/ -- Cempra Pharmaceuticals today announced a presentation on its novel fluoroketolide antibiotic, CEM-101, at the Infectious Diseases Society of America, 47th Annual Meeting, October 29 to November 1, 2009, in Philadelphia.

Susceptibility of CEM-101 and more than 25 other antibiotics was tested against 1,737 multidrug-resistant S. pneumoniae strains collected in 2008 from medical centers in the U.S., Europe and Latin America. CEM-101 demonstrated 100% coverage (100% inhibition at less than or equal to 1 microgram/ml) against these strains. Activity was slightly better than telithromycin (MIC90 of 0.25 microgram/ml for both; range of less than or equal to 0.008 to 1 for CEM-101 vs. less than or equal to 0.06 to 2 for telithromycin) and at least four-fold better than linezolid (MIC90 of 1 microgram/ml) or vancomycin (MIC90 of less than or equal to 1 microgram/ml). The study will be presented during a poster session on October 30.

CEM-101 is a new fluoroketolide antibiotic with potent and broad-spectrum activity against gram-positive and gram-negative pathogens, including multidrug-resistant strains, as well as non-bacterial pathogens such as Plasmodium falciparum. The compound recently completed a Phase 1 clinical trial and is in preparation for a Phase 2 trial in moderate to moderately-severe community-acquired bacterial pneumonia.

"The rise of multidrug-resistant organisms has become an increasing public health issue, particularly for vulnerable patient populations including those with challenging respiratory infections," said Prabhavathi Fernandes, Ph.D., Chief Executive Officer of Cempra Pharmaceuticals. "New medications are needed that are safe and effective against these difficult-to-treat pathogens. We believe that the growing database showing the potency and broad-spectrum activity of CEM-101, not only against the pneumococcal strains presented here, but against a variety of other pathogens, indicates the potential of CEM-101 as a future go-to antibiotic for clinicians."

About Cempra Pharmaceuticals

Founded in 2006, Cempra Pharmaceuticals is a privately-held, clinical-stage biotechnology company focused on developing antibacterials to address critical medical needs. Two lead products, both in late-stage clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra is well-funded and is committed to developing commercially viable products through consideration of pricing and reimbursement issues throughout its products' lifecycles. The company is also utilizing its proprietary chemistry technology to develop macrolides without antibacterial activity for non-antibiotic uses in motilin receptor activity, anti-inflammatory activity and GnRH receptor antagonism. Additional information about Cempra can be found at www.cempra.com.

    Media Contacts:
    Robert E. Flamm, Ph.D.
    Russo Partners, LLC
    (212) 845-4226
    Robert.flamm@russopartnersllc.com

    Tony Russo, Ph.D.
    Russo Partners, LLC
    (212) 845-4251
    Tony.russo@russopartnersllc.com

SOURCE Cempra Pharmaceuticals


'/>"/>
SOURCE Cempra Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Phase 2 Data From Oral NKTR-118 Presented at American College of Gastroenterology in San Diego
2. Medical Food Reduces Medical Costs and Use of Anticonvulsant Medication When Treating Diabetic Neuropathy, According to HealthCore Study Presented at ISPOR
3. Data from Jazz Pharmaceuticals First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia to be Presented at Upcoming Conferences
4. The Most Advanced Solution for the Reduction of Stretch Marks Based on TriPollar(R) Technology Presented at the Upcoming EADV Congress
5. Farletuzumab Data Presented on Phase II Clinical Trial in First-Relapsed Ovarian Cancer Subjects
6. OPAXIO(TM) Phase II Trial in Esophageal Cancer to be Presented in Proffered Session at the International Society of Gastrointestinal Oncology Annual Meeting
7. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
8. ClariVein(TM) Catheter for Varicose Veins: Further Clinical Trial Results to Be Presented
9. Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009
10. New Micro-Bland Embolization Technique with Embozene(TM) Microspheres to Be Presented at the International Medical Conference in Lisbon, Portugal
11. QVA149 Phase II Data Presented at the European Respiratory Society Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... Feb. 22, 2017 Summary Provides ... partnering deals and agreements entered into by the worlds ... http://www.reportlinker.com/p03605668-summary/view-report.html Description The Global Non-Small Cell Lung ... understanding and access to partnering deals and agreements entered ... - Trends in partnering deals - Top deals ...
(Date:2/22/2017)... and PUNE, India , February 22, 2017 ... was valued at $3,453 million in 2015 and is projected to reach $5,334 million ... implants segment held nearly two-fifths of the total market in 2015. ... ... ...
(Date:2/22/2017)... Feb. 22, 2017   Protein Sciences Corporation , ... Flublok® Influenza Vaccine , announced today that they donated ... Vaccine Introduction (PIVI) and the Mongolian Ministry of Health ... the flu.  The doses of Flublok have been distributed ... for health care workers, pregnant women, and ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... February 22, 2017 , ... Doctors on Liens is continuing its ... Dr. Steven H. Rauchman, practicing at North Valley Eye Medical Group in Mission ... premise liability and other personal injury cases. These injuries have a major impact ...
(Date:2/22/2017)... ... February 22, 2017 , ... The first-ever National ... organizations, advocates, and individuals join together to increase recognition about the risks of ... lives. , “Today we mark a nationwide movement to raise awareness about a ...
(Date:2/22/2017)... TX (PRWEB) , ... February 22, 2017 , ... ... the launch of ProGen™ PRP, the latest innovation in the delivery of Platelet ... wound care, aesthetics, cardiovascular and pain management, to accelerate tissue synthesis and provide ...
(Date:2/22/2017)... CT (PRWEB) , ... February 22, 2017 , ... The ... and the 2017 Forecast —on Thursday, February 23, 2017, at 1:00 PM ET. A ... webinar is part of the Interactive Webinar Series. , If you want to find ...
(Date:2/22/2017)... , ... February 22, 2017 , ... ... veterans who suffer from combat-related PTSD. , Established in 1977, our organization was ... the challenges of military returning to civilian life were evident and served as ...
Breaking Medicine News(10 mins):